Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;13(7):1521-1530.
doi: 10.1016/j.jcmg.2020.01.014. Epub 2020 Mar 18.

Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients

Kongkiat Chaikriangkrai  1 , Muhannad Aboud Abbasi  2 , Roberto Sarnari  2 , Ryan Dolan  2 , Daniel Lee  3 , Allen S Anderson  3 , Kambiz Ghafourian  3 , Sadiya S Khan  3 , Esther E Vorovich  3 , Jonathan D Rich  3 , Jane E Wilcox  3 , Julie A Blaisdell  2 , Clyde W Yancy  3 , James Carr  2 , Michael Markl  2
Affiliations

Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients

Kongkiat Chaikriangkrai et al. JACC Cardiovasc Imaging. 2020 Jul.

Abstract

Objectives: The purpose of this study was to examine prognostic value of T1- and T2-mapping techniques in heart transplant patients.

Background: Myocardial characterization using T2 mapping (evaluation of edema/inflammation) and pre- and post-gadolinium contrast T1 mapping (calculation of extracellular volume fraction [ECV] for assessment of interstitial expansion/fibrosis) are emerging modalities that have been investigated in various cardiomyopathies.

Methods: A total of 99 heart transplant patients underwent the magnetic resonance imaging (MRI) scans including T1- (n = 90) and T2-mapping (n = 79) techniques. Relevant clinical characteristics, MRI parameters including late gadolinium enhancement (LGE), and invasive hemodynamics were collected. Median clinical follow-up duration after the baseline scan was 2.4 to 3.5 years. Clinical outcomes include cardiac events (cardiac death, myocardial infarction, coronary revascularization, and heart failure hospitalization), noncardiac death and noncardiac hospitalization.

Results: Overall, the global native T1, postcontrast T1, ECV, and T2 were 1,030 ± 56 ms, 458 ± 84 ms, 27 ± 4% and 50 ± 4 ms, respectively. Top-tercile-range ECV (ECV >29%) independently predicted adverse clinical outcomes compared with bottom-tercile-range ECV (ECV <25%) (hazard ratio [HR]: 2.87; 95% confidence interval [CI]: 1.07 to 7.68; p = 0.04) in a multivariable model with left ventricular end-systolic volume and LGE. Higher T2 (T2 ≥50.2 ms) independently predicted adverse clinical outcomes (HR: 3.01; 95% CI: 1.39 to 6.54; p = 0.005) after adjustment for left ventricular ejection fraction, left ventricular end-systolic volume, and LGE. Additionally, higher T2 (T2 ≥50.2 ms) also independently predicted cardiac events (HR: 4.92; CI: 1.60 to 15.14; p = 0.005) in a multivariable model with left ventricular ejection fraction.

Conclusions: MRI-derived myocardial ECV and T2 mapping in heart transplant patients were independently associated with cardiac and noncardiac outcomes. Our findings highlight the need for larger prospective studies.

Keywords: T1 mapping; T2 mapping; extracellular volume fraction; heart transplantation; magnetic resonance imaging; natural history; prognosis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1. Baseline and Follow-Up
T1-mapping values were shown as mean global native T1, postcontrast T1, and extracellular volume fraction (ECV) in the left panel and as tercile categories in the right panels.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. Survival Curves Categorized by Myocardial ECV and T2 Mapping
(A) Extracellular volume fraction (ECV) for all clinical events (covariates = left ventricular end systolic volume index [LVESVI], presence of late gadolinium enhancement [LGE]). (B) ECV for cardiac events (unadjusted). (C) T2 mapping for all clinical events (covariates = left ventricular ejection fraction [LVEF], LVESVI, presence of LGE). (D) T2 mapping for cardiac events (covariates = LVEF).
See this image and copyright information in PMC

Comment in

References

    1. Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. J Am Coll Cardiol HF 2017;5:28–38. - PubMed
    1. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570–9. - PMC - PubMed
    1. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Cardiol Img 2012;5: 370–7. - PubMed
    1. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445–53. - PubMed
    1. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2014;7:250–8. - PMC - PubMed

Publication types